Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeUp to 80
SponsorUniversité Catholique de Louvain

About this trial

This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).

The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.

Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.

The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.

Eligibility criteria

Qualifiers

Diagnosis of lung cancer

Presence of precancerous lung lesions

Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease [COPD]) prior to any treatment

Control group: individuals without known lung disease

Disqualifiers

Systemic corticosteroid therapy > 10 mg/day prednisone (or equivalent)

Acute infection at the time of inclusion

Refusal or inability to provide informed consent (or assent, when applicable)

Chronic inflammatory lung disease currently treated with immunosuppressive therapy

Trial design

Treatments tested in this trial

  • Peripheral Blood Collection for Immune Profiling

Treatment groups

425 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.